WA
LLY icon

Winter & Associates’s Eli Lilly LLY Stock Holding History

Winter & Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Sell
360
-2
-0.6% -$2.04K 0.32% 43
2026
Q1 		$336K Buy
362
+13
+4% +$13.2K 0.29% 59
2025
Q4 		$375K Buy
+349
New +$334K 0.35% 57

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Winter & Associates's LLY Position: Q2 2026 in Review

Winter & Associates reduced its Eli Lilly (LLY) stake by 0.55% in Q2 2026, selling an estimated $2.04K and leaving 360 shares worth $431K. The position accounts for 0.32% of the portfolio, ranked #43.

Winter & Associates first reported a position in LLY in Q4 2025 and has held it in 3 quarters since. 4,614 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Winter & Associates held 360 shares of Eli Lilly worth $431K as of Q2 2026.
  • Winter & Associates sold 2 Eli Lilly shares in Q2 2026, an estimated $2.04K.
  • Eli Lilly made up 0.32% of Winter & Associates's portfolio in Q2 2026, its #43 holding.
  • Winter & Associates first reported a position in Eli Lilly in Q4 2025 and has held it in 3 quarters since.
  • 4,614 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Winter & Associates's 13F filing for Q2 2026, filed 9 Jul 2026.